ELEV
Elevation Oncology Inc

1,286
Mkt Cap
$21.63M
Volume
4.82M
52W High
$2.26
52W Low
$0.221
PE Ratio
-0.45
ELEV Fundamentals
Price
$0.365
Prev Close
$0.3729
Open
$0.3735
50D MA
$0.3598
Beta
0.71
Avg. Volume
662,729.09
EPS (Annual)
-$0.7767
P/B
0.46
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
News Placeholder
Allogene's Q1 Earnings In Line With Estimates, Sales Nil
Zacks·7mo ago
News Placeholder
Elevation Oncology downgraded as it halts lead asset on disappointing trials
Investing.com -- Wall Street cut rating on Elevation Oncology Inc (NASDAQ:ELEV) after the company announced it will discontinue development of its lead asset, EO-3021, due to disappointing efficacy in a Phase 1 trial. Analysts now see limited near-term catalysts, with Elevation pivoting to its HER3-targeted ADC, EO-1022, which is still in preclinical development.
investing.com·9mo ago
<
...
1
>

Latest ELEV News

View

Advertisement|Remove ads.

Advertisement|Remove ads.